- Home
- AIP vs STRO Comparison
AIP vs STRO Comparison
Compare AIP & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIP
- STRO
- Stock Information
- Founded
- AIP 2003
- STRO 2003
- Country
- AIP United States
- STRO United States
- Employees
- AIP N/A
- STRO N/A
- Industry
- AIP Semiconductors
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AIP Technology
- STRO Health Care
- Exchange
- AIP Nasdaq
- STRO Nasdaq
- Market Cap
- AIP 336.2M
- STRO 77.7M
- IPO Year
- AIP 2021
- STRO 2018
- Fundamental
- Price
- AIP $9.45
- STRO $0.75
- Analyst Decision
- AIP Strong Buy
- STRO Hold
- Analyst Count
- AIP 3
- STRO 7
- Target Price
- AIP $15.00
- STRO $3.97
- AVG Volume (30 Days)
- AIP 680.6K
- STRO 1.2M
- Earning Date
- AIP 07-31-2025
- STRO 08-12-2025
- Dividend Yield
- AIP N/A
- STRO N/A
- EPS Growth
- AIP N/A
- STRO N/A
- EPS
- AIP N/A
- STRO N/A
- Revenue
- AIP $61,309,000.00
- STRO $66,434,000.00
- Revenue This Year
- AIP $19.82
- STRO N/A
- Revenue Next Year
- AIP $17.29
- STRO N/A
- P/E Ratio
- AIP N/A
- STRO N/A
- Revenue Growth
- AIP 14.68
- STRO N/A
- 52 Week Low
- AIP $5.46
- STRO $0.52
- 52 Week High
- AIP $12.64
- STRO $5.17
- Technical
- Relative Strength Index (RSI)
- AIP 61.74
- STRO 44.48
- Support Level
- AIP $8.80
- STRO $0.73
- Resistance Level
- AIP $9.76
- STRO $0.79
- Average True Range (ATR)
- AIP 0.53
- STRO 0.06
- MACD
- AIP -0.04
- STRO 0.00
- Stochastic Oscillator
- AIP 63.10
- STRO 40.20
About AIP Arteris Inc.
Arteris Inc is a provider of semiconductor system IP, including interconnect and other intellectual property, (collectively, System IP) technology. Its IP technology manages the on-chip communications and IP block deployments in System-on-Chip (SoC) semiconductors and systems of chiplets. Its proprietary System IP solutions achieve this by connecting client IP blocks such as processors, memories, artificial intelligence/machine learning (AI/ML) accelerators, graphics subsystems, safety and security, and other input/output subsystems (I/Os) via multiple Network-on-Chips (NoCs). The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum profit from Asia Pacific.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.